ARS Pharmaceuticals, Inc (SPRY NASDAQ) stock market data APIs
$9.6366
-0.08(-0.8%)
as of September 17, 2025
Try our APIs with
free plan!
ARS Pharmaceuticals, Inc Financial Data Overview
Price chart is built with
Anychart
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Prev. Close
9.6366
Open
9.553
High
9.7962
Low
9.5319
52 wk Range
9.38-18.9
Market Cap
930 M
Shares Outstanding
98 826 K
Revenue
112 M
EPS
-0.46
Beta
0.924
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ARS Pharmaceuticals, Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ARS Pharmaceuticals, Inc data using free add-ons & libraries
Get ARS Pharmaceuticals, Inc Fundamental Data
ARS Pharmaceuticals, Inc Fundamental data includes:
- Net Revenue: 112 M
- EBITDA: -58 733 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.46
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARS Pharmaceuticals, Inc News
New
ARS Pharmaceuticals, Inc. (SPRY): A Bull Case Theory
We came across a bullish thesis on ARS Pharmaceuticals, Inc. on Value Degen’s Substack’s Substack by Unemployed Value Degen. In this article, we will summarize the bulls’ thesis on SPRY. ARS Pha...
ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair
– Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (G...
ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair
ADARx Pharmaceuticals – Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIE...
80% of Prior Authorizations Automated, 75% Fewer Denials: SPRY Unveils Prior Auth & Eligibility Solution for Rehab Therapy Clinics
New solution delivers real-time, unlimited eligibility verification and helps practices prepare for CMS’s 2026 mandate. SAN FRANCISCO, September 15, 2025--(BUSINESS WIRE)--SPRY Therapeutics Inc. to...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
